Literature DB >> 34235662

CRISPR Interference (CRISPRi) for Targeted Gene Silencing in Mycobacteria.

Andrew I Wong1, Jeremy M Rock2.   

Abstract

The genetic basis for Mycobacterium tuberculosis pathogenesis is incompletely understood. One reason for this knowledge gap is the relative difficulty of genetic manipulation of M. tuberculosis. To close this gap, we recently developed a robust CRISPR interference (CRISPRi) platform for programmable gene silencing in mycobacteria. In this chapter, we: (1) discuss some of the advantages and disadvantages of CRISPRi relative to more traditional genetic approaches; and (2) provide a protocol for the application of CRISPRi to reduce transcription of target genes in mycobacteria.

Entities:  

Keywords:  CRISPR; CRISPR interference; CRISPRi; Gene knockdown; Gene silencing; Transcriptional silencing

Year:  2021        PMID: 34235662     DOI: 10.1007/978-1-0716-1460-0_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  23 in total

1.  Recombineering in Mycobacterium tuberculosis.

Authors:  Julia C van Kessel; Graham F Hatfull
Journal:  Nat Methods       Date:  2006-12-17       Impact factor: 28.547

2.  Depletion of antibiotic targets has widely varying effects on growth.

Authors:  Jun-Rong Wei; Vidhya Krishnamoorthy; Kenan Murphy; Jee-Hyun Kim; Dirk Schnappinger; Tom Alber; Christopher M Sassetti; Kyu Y Rhee; Eric J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

3.  Serum and cell-mediated viral-specific delayed cutaneous basophil reactions during cytomegalovirus infection of guinea pigs.

Authors:  B P Griffith; P W Askenase; G D Hsiung
Journal:  Cell Immunol       Date:  1982-05-01       Impact factor: 4.868

4.  Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression.

Authors:  Lei S Qi; Matthew H Larson; Luke A Gilbert; Jennifer A Doudna; Jonathan S Weissman; Adam P Arkin; Wendell A Lim
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

5.  Global assessment of genomic regions required for growth in Mycobacterium tuberculosis.

Authors:  Yanjia J Zhang; Thomas R Ioerger; Curtis Huttenhower; Jarukit E Long; Christopher M Sassetti; James C Sacchettini; Eric J Rubin
Journal:  PLoS Pathog       Date:  2012-09-27       Impact factor: 6.823

6.  Protein inactivation in mycobacteria by controlled proteolysis and its application to deplete the beta subunit of RNA polymerase.

Authors:  Jee-Hyun Kim; Jun-Rong Wei; Joshua B Wallach; Rebekkah S Robbins; Eric J Rubin; Dirk Schnappinger
Journal:  Nucleic Acids Res       Date:  2010-11-12       Impact factor: 16.971

7.  High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism.

Authors:  Jennifer E Griffin; Jeffrey D Gawronski; Michael A Dejesus; Thomas R Ioerger; Brian J Akerley; Christopher M Sassetti
Journal:  PLoS Pathog       Date:  2011-09-29       Impact factor: 6.823

8.  Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor.

Authors:  Sabine Ehrt; Xinzheng V Guo; Christopher M Hickey; Marvin Ryou; Mercedes Monteleone; Lee W Riley; Dirk Schnappinger
Journal:  Nucleic Acids Res       Date:  2005-02-01       Impact factor: 16.971

9.  A CRISPR-Assisted Nonhomologous End-Joining Strategy for Efficient Genome Editing in Mycobacterium tuberculosis.

Authors:  Mei-Yi Yan; Si-Shang Li; Xin-Yuan Ding; Xiao-Peng Guo; Qi Jin; Yi-Cheng Sun
Journal:  mBio       Date:  2020-01-28       Impact factor: 7.867

10.  Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system.

Authors:  David Bikard; Wenyan Jiang; Poulami Samai; Ann Hochschild; Feng Zhang; Luciano A Marraffini
Journal:  Nucleic Acids Res       Date:  2013-06-12       Impact factor: 16.971

View more
  4 in total

1.  Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis.

Authors:  Nicholas C Poulton; Zachary A Azadian; Michael A DeJesus; Jeremy M Rock
Journal:  Antimicrob Agents Chemother       Date:  2022-08-03       Impact factor: 5.938

2.  CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis.

Authors:  Shuqi Li; Nicholas C Poulton; Jesseon S Chang; Zachary A Azadian; Michael A DeJesus; Nadine Ruecker; Matthew D Zimmerman; Kathryn A Eckartt; Barbara Bosch; Curtis A Engelhart; Daniel F Sullivan; Martin Gengenbacher; Véronique A Dartois; Dirk Schnappinger; Jeremy M Rock
Journal:  Nat Microbiol       Date:  2022-05-30       Impact factor: 30.964

3.  The essential M. tuberculosis Clp protease is functionally asymmetric in vivo.

Authors:  Felipe B d'Andrea; Nicholas C Poulton; Ruby Froom; Kayan Tam; Elizabeth A Campbell; Jeremy M Rock
Journal:  Sci Adv       Date:  2022-05-04       Impact factor: 14.957

4.  Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis.

Authors:  Barbara Bosch; Michael A DeJesus; Nicholas C Poulton; Wenzhu Zhang; Curtis A Engelhart; Anisha Zaveri; Sophie Lavalette; Nadine Ruecker; Carolina Trujillo; Joshua B Wallach; Shuqi Li; Sabine Ehrt; Brian T Chait; Dirk Schnappinger; Jeremy M Rock
Journal:  Cell       Date:  2021-07-22       Impact factor: 41.582

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.